First, 2020 emerged as the peak year for both overall IL-1 inhibitor-related AEs and anakinra-specific occurrences, a pattern that aligns with the widespread off-label use of IL-1 inhibitors—including anakinra—for the treatment of coronavirus disease 2019 (COVID-19) during this period [14,15,16], especially mitigating the “cytokine storm” in critically ill COVID-19 patients [17]. This evidence concerns the gene IL1B and COVID-19.